BioMAS
 

Home > Applications > Psoriasis

Psoriasis is a common T cell-mediated autoimmune inflammatory disease, characterized by thickening of the inner layer of skin as a result of increased proliferation and aberrant differentiation of a certain type of epidermal cells. Psoriatic epidermal cells continuously produce enormously wide spectrum of cytokines showing distinct biological functions.

AS101 has shown an inhibitory effect on IL-17 secretion from activated mice spleen cells. AS101 was also shown to inhibit caspase-1 and subsequently to decrease IL-18 expression. It is thus proposed that AS101 treatment will alleviate Psoriasis by decreasing IL-17 and IL-18 expression. In addition, AS101 has been shown to inhibit the pro-inflammatory VLA-4 Integrin, which has an important role in the generation of the immune response, by its effect on leukocytes activation. Furthermore, blockade of VLA-4 has shown to prevent or ameliorate disease severity in animal autoimmune models.

MOA - Psoriasis

BioMAS has recently conducted a phase II clinical trial, placebo controlled, to test the safety and efficacy of a 4% AS101 ointment for the treatment of mild to moderate psoriasis. The results show that 62.5% of the AS101 treated patients reached more than 50% improvement in modified PASI as compared to 13% of the placebo treated patients. No serious adverse events were reported in the trial.

AS101’s ability to inhibit specific integrins and specifically decrease expression of pro-inflammatory integrins, together with its superior safety profile, marks it as a good candidate for a novel treatment for psoriasis.
Results


Psoriasis Treatment - Example 1


Psoriasis Treatment - Example 2


Psoriasis Treatment - Example 3


Psoriasis-4-Big.jpg
   

   Back to top